A medication used to treat depression, anxiety, OCD, and PTSD, as well as the symptoms of menopause such as hot flashes.


A selective serotonin reuptake inhibitor used to treat major depressive disorder, panic disorder, OCD, social phobia, generalized anxiety disorder, the vasomotor symptoms of menopause, and premenstrual dysphoric disorder.


Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[26] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[32,33] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[13] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[Read more



Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[29] One form of paroxetine,... Read more


Paroxetine treats the symptoms of depression, various anxiety disorders, posttraumatic stress disorder, obsessive-compulsive disorder, and the vasomotor symptoms of menopause via the inhibition of serotonin reuptake.[ Read more

Mechanism of action

Paroxetine enhances serotonergic activity via the inhibition presynaptic reuptake of serotonin by the serotonin (SERT) receptor.[ Read more


Paroxetine is readily absorbed from the gastrointestinal tract. Due to the first-pass metabolism, the bioavailability ranges from 30-60%. Cmax is attained 2 to 8 hours after an oral dose.[ Read more

Protein binding

Paroxetine is 95% bound to plasma proteins.[7, Read more

Volume of distribution

Paroxetine has a large volume of distribution and is found throughout the body, including in the central nervous system. Only 1% of the drug is found in the plasma.[29]Paroxetine is found in the breast milk at concent... Read more


The apparent oral clearance of paroxetine is 167 L/h.[14] The clearance... Read more

Half life

The mean elimination half-life of paroxetine is about 21 hours.[29] In healthy young subjects, mean elimination half-life was found to be 17.3 hours.[ Read more

Route of elimination

About 2/3 of a single paroxetine dose is found to be excreted in the urine and the remainder is found to be excreted in feces. Almost all of the dose is eliminated as metabolites; 3% is found to be excreted as unchanged paroxetine.[ Read more


The acute LD50 in mice and rats is 350 mg/kg.[35]

Overdose information

The lowest dose of paroxetine reported to lead to a fatal outcome is approximately 400 mg. The largest reported paroxetine overdose fr... Read more

Adverse Effects


  • Dose Form:
    • Capsule
  • Regions: US
  • Patient Conditions:
      • Name: Pregnancy
      • Drugbank Id: DBCOND0018394
  • Recommended Actions:
    • Do not administer within 14 days of MAO inhibitors
    • Do not administer with MAO inhibitors
  • Regions: US
  • Patient Conditions Associated With:
      • Name: Serotonin Syndrome
      • Drugbank Id: DBCOND0005988
  • With Categories:
      • Name: Monoamine Oxidase Inhibitors
      • Drugbank Id: DBCAT001004
      • Mesh Id: D008996
  • Regions: US
  • Patient Conditions:
      • Name: Known hypersensitivity to the drug or any of the ingredients
      • Drugbank Id: DBCOND0118758
  • Regions: US
  • With Drugs:
      • Name: Thioridazine
      • Drugbank Id: DB00679
  • Regions: US
  • With Drugs:
      • Name: Pimozide
      • Drugbank Id: DB01100

Food Interactions

  • Avoid alcohol.
  • Take with or without food. Food does not significantly affect absorption.


Type in a drug name to check for interaction with Paroxetine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
The serum concentration of (R)-warfarin can be increased when it is combined with Paroxetine.
The serum concentration of (S)-Warfarin can be increased when it is combined with Paroxetine.
The metabolism of Paroxetine can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
The therapeutic efficacy of Paroxetine can be decreased when used in combination with 1,10-Phenanthroline.
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with 2,4-thiazolidinedione.
The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Paroxetine.
3,5-diiodothyropropionic acid
The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Paroxetine.
The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Paroxetine.
The risk or severity of adverse effects can be increased when Paroxetine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
The risk or severity of hemorrhage can be increased when Paroxetine is combined with 4-hydroxycoumarin.
The metabolism of 4-Methoxyamphetamine can be decreased when combined with Paroxetine.
The metabolism of Paroxetine can be decreased when combined with 5-methoxy-N,N-dimethyltryptamine.
The metabolism of 6-O-benzylguanine can be decreased when combined with Paroxetine.
The risk or severity of adverse effects can be increased when Paroxetine is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Paroxetine.
The metabolism of 8-azaguanine can be decreased when combined with Paroxetine.
The metabolism of 8-chlorotheophylline can be decreased when combined with Paroxetine.
The metabolism of 9-aminocamptothecin can be decreased when combined with Paroxetine.
The metabolism of 9-Deazaguanine can be decreased when combined with Paroxetine.
36 References
  1. 1 . Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96.PubMed: 16272179
  2. 2 . Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999 Aug;175:120-6.PubMed: 10627793
  3. 3 . Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb;16(1):3-8.PubMed: 8834412
  4. 4 . Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B: Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998 Aug;18(4):274-81.PubMed: 9690692
  5. 5 . Zhang D, Cheng Y, Wu K, Ma Q, Jiang J, Yan Z: Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. BMC Urol. 2019 Jan 3;19(1):2. doi: 10.1186/s12894-018-0431-7.PubMed: 30606186
  6. 6 . Nevels RM, Gontkovsky ST, Williams BE: Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required. Psychopharmacol Bull. 2016 Mar 1;46(1):77-104.PubMed: 27738376
  7. 7 . Hiemke C: [Paroxetine: pharmacokinetics and pharmacodynamics]. Fortschr Neurol Psychiatr. 1994 Sep;62 Suppl 1:2-8.PubMed: 7959522
  8. 8 . van Zeeland YR, Schoemaker NJ, Haritova A, Smit JW, van Maarseveen EM, Lumeij JT, Fink-Gremmels J: Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. J Vet Pharmacol Ther. 2013 Feb;36(1):51-8. doi: 10.1111/j.1365-2885.2012.01391.x. Epub 2012 Mar 21.PubMed: 22435778
  9. 9 . Tang SW, Helmeste D: Paroxetine. Expert Opin Pharmacother. 2008 Apr;9(5):787-94. doi: 10.1517/14656566.9.5.787 .PubMed: 18345955
  10. 10 . Uttamsingh V, Gallegos R, Liu JF, Harbeson SL, Bridson GW, Cheng C, Wells DS, Graham PB, Zelle R, Tung R: Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine. J Pharmacol Exp Ther. 2015 Jul;354(1):43-54. doi: 10.1124/jpet.115.223768. Epub 2015 May 5.PubMed: 25943764
  11. 11 . Davis BA, Nagarajan A, Forrest LR, Singh SK: Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter. Sci Rep. 2016 Apr 1;6:23789. doi: 10.1038/srep23789.PubMed: 27032980
  12. 12 . Calisto V, Ferreira CI, Oliveira JA, Otero M, Esteves VI: Adsorptive removal of pharmaceuticals from water by commercial and waste-based carbons. J Environ Manage. 2015 Apr 1;152:83-90. doi: 10.1016/j.jenvman.2015.01.019. Epub 2015 Jan 21.PubMed: 25617872
  13. 13 . Foster RH, Goa KL: Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.PubMed: 23338224
  14. 14 . van Harten J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993 Mar;24(3):203-20. doi: 10.2165/00003088-199324030-00003.PubMed: 8384945
  15. 15 . Altamura AC, Moro AR, Percudani M: Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994 Mar;26(3):201-14. doi: 10.2165/00003088-199426030-00004.PubMed: 8194283
  16. 16 . Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1387-96. doi: 10.1097/01.chi.0000138356.29099.f1.PubMed: 15502598
  17. 17 . Kato O, Misawa H: Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine. Prim Care Companion J Clin Psychiatry. 2005;7(4):202. doi: 10.4088/pcc.v07n0412a.PubMed: 16163406
  18. 18 . Gray SL, Hanlon JT: Anticholinergic medication use and dementia: latest evidence and clinical implications. Ther Adv Drug Saf. 2016 Oct;7(5):217-224. doi: 10.1177/2042098616658399. Epub 2016 Jul 18.PubMed: 27695623
  19. 19 . Morishita S, Arita S: Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Hum Psychopharmacol. 2003 Aug;18(6):479-82. doi: 10.1002/hup.508.PubMed: 12923828
  20. 20 . Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.PubMed: 19515014
  21. 21 . Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8.PubMed: 10869387
  22. 22 . Fujishiro J, Imanishi T, Onozawa K, Tsushima M: Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002 Nov 15;454(2-3):183-8. doi: 10.1016/s0014-2999(02)02557-8.PubMed: 12421645
  23. 23 . Peng L, Gu L, Li B, Hertz L: Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects. Curr Neuropharmacol. 2014 Jul;12(4):365-79. doi: 10.2174/1570159X12666140828221720.PubMed: 25342944
  24. 24 . Masand PS, Gupta S, Schwartz TL, Virk S, Lockwood K, Hameed A, King M, Kaplan DS: Paroxetine in Patients With Irritable Bowel Syndrome: A Pilot Open-Label Study. Prim Care Companion J Clin Psychiatry. 2002 Feb;4(1):12-16. doi: 10.4088/pcc.v04n0105.PubMed: 15014729
  25. 25 . Shortall SE, Spicer CH, Ebling FJ, Green AR, Fone KC, King MV: Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone. Addict Biol. 2016 Nov;21(6):1127-1139. doi: 10.1111/adb.12283. Epub 2015 Jul 16.PubMed: 26180025
  26. 26 . Prabina Shrestha; Sara Abdijadid (2018). Paroxetine. NIH StatPearls.
  27. 27 . Siu Wa Tang and Daiga Helmeste (2008). Expert opinion on pharmacotherapeutics; Paroxetine. Taylor and Francis online.
  28. 28 . Paxil CR FDA label Link
  29. 29 . Paroxetine FDA Label Link
  30. 30 . Brisdelle FDA label Link
  31. 31 . GSK monograph, Paxil Link
  32. 32 . Paxil Link
  33. 33 . Putting GlaxoSmithKline to the test over paroxetine Link
  34. 34 . Annotation of CPIC Guideline for paroxetine and CYP2D6 Link
  35. 35 . Sandoz paroxetine tablets Link
  36. 36 . Paroxetine, psychopharmacology institute Link